Duration of Chemotherapy with Topotecan Influences Survival in Recurrent Ovarian Cancer: A Meta-analysis
Objective: This meta-analysis compares the feasibility, safety and clinical outcome of long-term therapy with topotecan vs. standard treatment duration in patients with recurrent ovarian cancer. Materials and Methods: Data of 523 patients from five clinical trials were reviewed and retrospectively a...
Saved in:
Published in | Anticancer research Vol. 27; no. 3B; pp. 1581 - 1588 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Attiki
International Institute of Anticancer Research
01.05.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective: This meta-analysis compares the feasibility, safety and clinical outcome of long-term therapy with topotecan vs.
standard treatment duration in patients with recurrent ovarian cancer. Materials and Methods: Data of 523 patients from five
clinical trials were reviewed and retrospectively allocated into two groups. Those patients who received 6 or fewer courses
were compared to those with 7 or more courses of intravenous topotecan. Response rates, overall survival and toxicity profiles
were compared between these groups. Results: One hundred and fifty-two (29%) patients received 7 or more courses and 371 patients
(71%) received up to 6 courses of topotecan. Hematological toxicity was significant but similar in both treatment groups and
was not cumulative. Non-hematological toxicity was generally mild. Eighty-seven (17%) patients responded to topotecan treatment,
66 of these patients received 7 or more courses of therapy. In total, 14 patients experienced their initial response at or
after course 6 of therapy. Within the subset of patients with response or disease stabilization at course 6, those who stopped
treatment at course 6 for reasons other than progressive disease or adverse events had a median survival of 83.6 weeks and
those who continued treatment for longer than 6 courses had a significantly longer median survival of 107.0 weeks. Conclusion:
Chemotherapy with 7 or more courses of topotecan in recurrent ovarian cancer is feasible with no evidence of cumulative toxicity.
The results of this retrospective analysis suggest a potential for late response and a survival benefit for those patients
without disease progression who continue topotecan therapy beyond 6 cycles of treatment. |
---|---|
AbstractList | Objective: This meta-analysis compares the feasibility, safety and clinical outcome of long-term therapy with topotecan vs.
standard treatment duration in patients with recurrent ovarian cancer. Materials and Methods: Data of 523 patients from five
clinical trials were reviewed and retrospectively allocated into two groups. Those patients who received 6 or fewer courses
were compared to those with 7 or more courses of intravenous topotecan. Response rates, overall survival and toxicity profiles
were compared between these groups. Results: One hundred and fifty-two (29%) patients received 7 or more courses and 371 patients
(71%) received up to 6 courses of topotecan. Hematological toxicity was significant but similar in both treatment groups and
was not cumulative. Non-hematological toxicity was generally mild. Eighty-seven (17%) patients responded to topotecan treatment,
66 of these patients received 7 or more courses of therapy. In total, 14 patients experienced their initial response at or
after course 6 of therapy. Within the subset of patients with response or disease stabilization at course 6, those who stopped
treatment at course 6 for reasons other than progressive disease or adverse events had a median survival of 83.6 weeks and
those who continued treatment for longer than 6 courses had a significantly longer median survival of 107.0 weeks. Conclusion:
Chemotherapy with 7 or more courses of topotecan in recurrent ovarian cancer is feasible with no evidence of cumulative toxicity.
The results of this retrospective analysis suggest a potential for late response and a survival benefit for those patients
without disease progression who continue topotecan therapy beyond 6 cycles of treatment. This meta-analysis compares the feasibility, safety and clinical outcome of long-term therapy with topotecan vs. standard treatment duration in patients with recurrent ovarian cancer. Data of 523 patients from five clinical trials were reviewed and retrospectively allocated into two groups. Those patients who received 6 or fewer courses were compared to those with 7 or more courses of intravenous topotecan. Response rates, overall survival and toxicity profiles were compared between these groups. One hundred and fifty-two (29%) patients received 7 or more courses and 371 patients (71%) received up to 6 courses of topotecan. Hematological toxicity was significant but similar in both treatment groups and was not cumulative. Non-hematological toxicity was generally mild. Eighty-seven (17%) patients responded to topotecan treatment, 66 of these patients received 7 or more courses of therapy. In total, 14 patients experienced their initial response at or after course 6 of therapy. Within the subset of patients with response or disease stabilization at course 6, those who stopped treatment at course 6 for reasons other than progressive disease or adverse events had a median survival of 83.6 weeks and those who continued treatment for longer than 6 courses had a significantly longer median survival of 107.0 weeks. Chemotherapy with 7 or more courses of topotecan in recurrent ovarian cancer is feasible with no evidence of cumulative toxicity. The results of this retrospective analysis suggest a potential for late response and a survival benefit for those patients without disease progression who continue topotecan therapy beyond 6 cycles of treatment. |
Author | VOLKER MÃBUS DIRK G. KIEBACK SABINE K. KAUBITZSCH |
Author_xml | – sequence: 1 givenname: Volker surname: MOBUS fullname: MOBUS, Volker organization: Department of Obstetrics and Gynecology, Stadtische Kliniken Frankfurt-Hoechst, Frankfurt, Germany – sequence: 2 givenname: Dirk G surname: KIEBACK fullname: KIEBACK, Dirk G organization: Department of Obstetrics and Gynecology, HELIOS Medical Center, Aue, Germany – sequence: 3 givenname: Sabine K surname: KAUBITZSCH fullname: KAUBITZSCH, Sabine K organization: Glaxo SmithKline Clinical Development and Medical Affairs, New Frontiers Science Park, Harlow, Essex, United Kingdom |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18853792$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17595779$$D View this record in MEDLINE/PubMed |
BookMark | eNpFz1tLwzAcBfAgE3fRryB50bdCLk2T-jbrbTAZ6N7Lv21qIm1aknZj396CE5_Oy4_DOUs0c53TF2hBZUojKTiZoQVhgkSSEDFHyxC-CUmSVPErNKdSpELKdIHM0-hhsJ3DXY0zo9tuMNpDf8JHOxi87_pu0CU4vHF1M2pX6oA_R3-wB2iwdfhDl6P32g14dwBvJ5jBhPwDXuN3PUAEDppTsOEaXdbQBH1zzhXavzzvs7dou3vdZOttZJgkQ1QyoYHTpIhFTQAklbxKioRyXXFSMMFKUcq6qolQLBYxF4wrxjlRQqUsifkK3f7W9mPR6irvvW3Bn_K_xxO4OwMIJTS1n-ba8O-UElymbHL3v87YL3O0XuehhaaZankOnsmcP-ZUKMp_AOMdbqE |
ContentType | Journal Article |
Copyright | 2007 INIST-CNRS |
Copyright_xml | – notice: 2007 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1791-7530 |
EndPage | 1588 |
ExternalDocumentID | 17595779 18853792 ar27_3B_1581 |
Genre | Meta-Analysis Journal Article |
GroupedDBID | - 23M 53G 55 5GY 5RE 5VS ABFLS ADACO ADBBV ADBIT AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL DIK EBS EJD F5P H13 KQ8 L7B OK1 P2P RHF RHI SJN UDS VRB X7M ZGI ZXP --- .55 .GJ AAUGY AFFNX BTFSW IQODW W8F AIZAD CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-h270t-c25ea316b45f0aa7173d6b613ed30b252c5c7fdf058245435238233085892643 |
ISSN | 0250-7005 |
IngestDate | Sat Sep 28 07:42:34 EDT 2024 Sun Oct 22 16:09:06 EDT 2023 Tue Nov 23 16:34:04 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3B |
Keywords | Antineoplastic agent Relapse Enzyme ovarian cancer Ovary cancer DNA topoisomerase Enzyme inhibitor meta-analysis Topotecan Malignant tumor Long term Survival Female genital diseases Metaanalysis Ovarian diseases Chemotherapy Isomerases Cancerology Treatment maintenance long-term |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-h270t-c25ea316b45f0aa7173d6b613ed30b252c5c7fdf058245435238233085892643 |
PMID | 17595779 |
PageCount | 8 |
ParticipantIDs | pubmed_primary_17595779 pascalfrancis_primary_18853792 highwire_smallpub3_ar27_3B_1581 |
PublicationCentury | 2000 |
PublicationDate | 2007-05-01 |
PublicationDateYYYYMMDD | 2007-05-01 |
PublicationDate_xml | – month: 05 year: 2007 text: 2007-05-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Attiki |
PublicationPlace_xml | – name: Attiki – name: Greece |
PublicationTitle | Anticancer research |
PublicationTitleAlternate | Anticancer Res |
PublicationYear | 2007 |
Publisher | International Institute of Anticancer Research |
Publisher_xml | – name: International Institute of Anticancer Research |
SSID | ssj0066983 |
Score | 1.8659891 |
SecondaryResourceType | review_article |
Snippet | Objective: This meta-analysis compares the feasibility, safety and clinical outcome of long-term therapy with topotecan vs.
standard treatment duration in... This meta-analysis compares the feasibility, safety and clinical outcome of long-term therapy with topotecan vs. standard treatment duration in patients with... |
SourceID | pubmed pascalfrancis highwire |
SourceType | Index Database Publisher |
StartPage | 1581 |
SubjectTerms | Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Biological and medical sciences Clinical Trials as Topic Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Ovarian Neoplasms - drug therapy Retrospective Studies Survival Topotecan - administration & dosage Topotecan - adverse effects Treatment Outcome Tumors |
Title | Duration of Chemotherapy with Topotecan Influences Survival in Recurrent Ovarian Cancer: A Meta-analysis |
URI | http://ar.iiarjournals.org/content/27/3B/1581.abstract https://www.ncbi.nlm.nih.gov/pubmed/17595779 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLbSPkx7mXZfdun8sD4hKsCAYW-QZCvL0koZmaq9IANGrdSSKCGVtp-yX7tjbG7VpF1eEAJkLJ-Pw-fj4-8g9C7LCS-4aeseF6GblBvwSaWmzjOLE6NwfbeuRbA4c09X9qcL52I0-tnLWtpX6Un247f7Sv7HqnAN7Cp2yf6DZdtG4QKcg33hCBaG41_ZeLrftoxP7PxXu6m-y-hqvN4IDQYmwn6qEskOHAX4httaaUNQRqXOdH4LU2Z4cCIwsJW71Re8YjpTmiV9DhuUIv4tHtSUVFAbUv56_nk-W2oLsfzukeOJdey74arlm9NoOdc-nmjzaBYGky7AGoTR2Uybw41gFUbxty9qAauJRtAu90_OUAdhzEG-Q69zy37npK8DJqZTw5AL3Fz6YuqbOsymjL6zlkICCpQk7Lle05G1X3p239zUhgeG5DtU1qwZKm7f-RO2-Ylsa9GEhIlo8wAdEFNUZZhG8-Yf77q-FHhtui20Z9VbekrTItGW7eBbK2SRlDtTl5rCxA_RAzX3wIEE0iM04uVjdG-hsiueoMsGT3hd4D6esMATbvGEOzzhBk_4qsQtnrDCE5Z4eo8DPEDTUxR_mMWTU11V4tAvLWpUemY5nBHTTW2nMBgTmRu5mwIT5DkxUsuxMiejRV4YjmfZDjBwSywvE6Dzng-MmzxDh-W65C8Qtn2xMExd02O57aU0NQ1g0GmWA0_MHJuO0dtm9JLdDbu-hgEjSd8eY3Q0GNRkI2VZEtMD6kl9a4yey1Hu7ijTvPxj46_Q_Q7Vr9Fhtd3zN8A6q_SoBsAvJSaDjA |
link.rule.ids | 314,780,784 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Duration+of+Chemotherapy+with+Topotecan+Influences+Survival+in+Recurrent+Ovarian+Cancer%3A+A+Meta-analysis&rft.jtitle=Anticancer+research&rft.au=VOLKER+M%C3%83%C2%96BUS&rft.au=DIRK+G.+KIEBACK&rft.au=SABINE+K.+KAUBITZSCH&rft.date=2007-05-01&rft.pub=International+Institute+of+Anticancer+Research&rft.issn=0250-7005&rft.eissn=1791-7530&rft.volume=27&rft.issue=3B&rft.spage=1581&rft_id=info%3Apmid%2F17595779&rft.externalDBID=n%2Fa&rft.externalDocID=ar27_3B_1581 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0250-7005&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0250-7005&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0250-7005&client=summon |